Maxcyte logo

MaxCyte

MaxCyte® is a leading cell-engineering company advancing the discovery, development, and commercialization of next-generation cell therapies. The company's Flow Electroporation® technology and SeQure DX™ gene editing risk assessment services provide precise, efficient, and scalable solutions for cell engineering. Supported by comprehensive scientific, technical, and regulatory expertise, MaxCyte’s ExPERT™ platform enables researchers to engineer a wide range of cell types and payloads, accelerating the development of safe and effective treatments. With more than 25 years of experience in cell engineering, MaxCyte continues to shape the future of medicine.

Content by MaxCyte

Graphic showing a DNA strand and red blood cells

Moving Gene Editing Advances Into the Clinic

July Digest 2025
July 2025, Issue 1

What Causes an Earworm?

Memory-enhancing neural networks may also drive involuntary musical loops in the brain.

View this Issue
Explore synthetic DNA’s many applications in cancer research

Weaving the Fabric of Cancer Research with Synthetic DNA

Twist Bio 
Illustrated plasmids in bright fluorescent colors

Enhancing Elution of Plasmid DNA

cytiva logo
An illustration of green lentiviral particles.

Maximizing Lentivirus Recovery

cytiva logo
Explore new strategies for improving plasmid DNA manufacturing workflows.

Overcoming Obstacles in Plasmid DNA Manufacturing

cytiva logo

Products

sartorius-logo

Introducing the iQue 5 HTS Platform: Empowering Scientists  with Unbeatable Speed and Flexibility for High Throughput Screening by Cytometry

parse_logo

Vanderbilt Selects Parse Biosciences GigaLab to Generate Atlas of Early Neutralizing Antibodies to Measles, Mumps, and Rubella

shiftbioscience

Shift Bioscience proposes improved ranking system for virtual cell models to accelerate gene target discovery

brandtechscientific-logo

BRANDTECH Scientific Launches New Website for VACUU·LAN® Lab Vacuum Systems